Komori
Treasury Shares4534Mochida Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice Regarding the Status of Share Repurchases

In September 2026, the company acquired 57,400 treasury shares for approximately ¥187 million. Cumulative acquisitions under the resolution of the Board of Directors totaled 325,900 shares, at approximately ¥1.055 billion.

Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
186619000
¥
Wording
Definitive
How definitive the wording is.

Progress against acquisition limit

Market purchases on the Tokyo Stock Exchange

Resolved 30 March 2026 / Acquisition period 18 May 2026–18 December 2026

61.5%
Cumulative utilization rate
Limit204,100 株 remaining
Number of Shares530,000 shares (maximum)
52.7%
Cumulative utilization rate
LimitShares 61.5%945,097,000 円 remaining
Amount¥2,000,000,000 (maximum)

The darker band is the portion acquired this time (1 September 2026 to 30 September 2026 (based on trade executions)). At this pace, the share-count limit will be reached first, and the acquisition will end without using the full monetary limit.

Number of Shares
Limit530,000 shares (maximum)
Cumulative total325,900 shares (as of 30 September 2026)
Current57,400 shares
Amount
Limit¥2,000,000,000 (maximum)
Cumulative total¥1,054,903,000 (as of 30 September 2026)
Current¥186,619,000
Percentage of total issued shares1.50%
Average acquisition price for this transaction (calculated)¥3,251 per shareCurrent acquisition price ÷ current number of shares acquired

消化率と残りは、会社が示した累計・今回と上限から算出しています。進捗率=上限に対してどこまで使ったかの割合です。

Progress against acquisition limit
ItemDetails
Total number of shares acquired in this transaction57,400 shares
Total current acquisition price¥186,619,000
Acquisition date/acquisition period1 September 2026 to 30 September 2026 (based on trade executions)
Method of acquisitionMarket purchases on the Tokyo Stock Exchange
Cumulative number of shares acquired325,900 shares (as of 30 September 2026)
Cumulative acquisition cost¥1,054,903,000 (as of 30 September 2026)
Resolution date30 March 2026
Maximum number of shares to be acquired530,000 shares (maximum)
Total acquisition price¥2,000,000,000 (maximum)
Acquisition period under the resolution18 May 2026–18 December 2026
Percentage of total issued shares1.50%
Items this document does not state (2)
Whether acquisition has been completedAverage Acquisition Price

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This is a report on the status of the purchases; no reason for the purchases is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Status of Share Repurchases | Mochida Pharmaceutical Co.,Ltd. (4534) timely disclosure | Komori